0.16
+203.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eom Pharmaceutical Holdings
Its shares trade under the ticker IMUC. It has been listed since 19 September 2006.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company is headquartered in Westlake Village, California. The company went IPO on 2006-09-19. The firm is developing immune-based therapies for the treatment of cancers. The firm's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. The company is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Sept 2006
- Employees
- 4
- Website
- imuc.com ↗
Leadership
Pay as last reported
- Mr. Eli GoldbergerChairman of the Board, Chief Operating Officer, since 2021
- Dr. Irach TaraporewalaPresident, Chief Executive Officer, Director, since 2021$36,483
- Mr. Wayne DansonChief Financial Officer, Treasurer$12,500
- Dr. Shalom HirschmanChief Scientific Officer
- Mr. Frank DouglasIndependent Director
- Ms. Julie KampfIndependent Director
- Mr. Robert LehmanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research and Development (R&D) capabilities, allowing for the discovery and development of innovative immunotherapy treatments.
- Extensive intellectual property portfolio, providing a competitive advantage and potential licensing opportunities.
- Skilled and experienced team of scientists and medical professionals, contributing to the development of cutting-edge therapies.
Weaknesses
- Limited financial resources, potentially impacting the speed of product development and commercialization efforts.
- Reliance on a small pipeline of drug candidates, increasing the risk associated with product failure or limited market opportunities.
- Vulnerability to regulatory challenges and stringent approval processes in the healthcare industry, potentially delaying market entry.
Opportunities
- Growing demand for immunotherapy treatments, driven by increasing prevalence of cancer and other immune system disorders.
- Collaborative partnerships and licensing agreements with larger pharmaceutical companies, facilitating access to resources and expanding market reach.
- Potential expansion into international markets, capitalizing on global healthcare trends and geographical diversification.
Threats
- Intense competition from established pharmaceutical companies and emerging biotechnology firms, challenging market penetration and pricing strategies.
- Uncertainty surrounding healthcare policy changes and regulatory reforms, potentially impacting reimbursement rates and market access.
- Technological advancements and new discoveries in the field, increasing the risk of obsolescence or the need for continuous innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.